Alerts will be sent to your verified email
Verify Email
VENUSREM
|
Venus Remedies
|
Lincoln Pharma
|
Jagsonpal Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
8.87 % | 15.1 % | 16.01 % |
|
5yr average Equity Multiplier
|
1.32 | 1.26 | 1.27 |
|
5yr Average Asset Turnover Ratio
|
0.96 | 0.82 | 1.09 |
|
5yr Avg Net Profit Margin
|
6.91 % | 14.59 % | 12.08 % |
|
Price to Book
|
1.78 | 1.3 | 4.47 |
|
P/E
|
13.89 | 11.66 | 27.64 |
|
5yr Avg Cash Conversion Cycle
|
46.96 Days | -6.41 Days | 2.39 Days |
|
Inventory Days
|
75.64 Days | 43.91 Days | 37.29 Days |
|
Days Receivable
|
54.28 Days | 91.75 Days | 15.63 Days |
|
Days Payable
|
58.86 Days | 128.38 Days | 59.94 Days |
|
5yr Average Interest Coverage Ratio
|
396.11 | 63.13 | 66.99 |
|
5yr Avg ROCE
|
8.42 % | 19.81 % | 18.99 % |
|
5yr Avg Operating Profit Margin
|
10.14 % | 18.35 % | 13.23 % |
|
5 yr average Debt to Equity
|
0.08 | 0.0 | 0.01 |
|
5yr CAGR Net Profit
|
-6.01 % | 5.76 % | 26.54 % |
|
5yr Average Return on Assets
|
6.69 % | 11.92 % | 12.71 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
41.76 % | 49.78 % | 67.39 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 3.44 % | -1.32 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Venus Remedies
|
Lincoln Pharma
|
Jagsonpal Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|